"The 340B program has evolved into a profit-making opportunity for participating non-profit hospitals, encouraging them to use more expensive cancer drugs to increase the spread between the 340B discounted purchase price and the amount billed to insurers and patients."
"Currently, patients are not prioritized as the beneficiaries of 340B. Legislation tucked into the New York State Senate's budget resolution would only make matters worse."
"Our work is deeply patient-centric and focused on maximizing positive outcomes for patients, and we advocate for the 340B program to return to its original mission and do the same."
"An analysis of insurer claims published in the New England Journal of Medicine found that 340B eligible hospitals kept nearly two-thirds of what insurers paid for infused drugs."
CancerCare provides free support services for cancer patients and emphasizes the need for accountability in the 340B Drug Pricing Program. The program is currently exploited by non-profit hospitals for profit, leading to increased costs for patients and insurers. Legislation in New York threatens to worsen these issues. CancerCare calls for the rejection of the state Senate's budget proposal, aiming to realign the program with its original mission of benefiting vulnerable patients. In 2025, oncology social workers handled nearly 1,000 inquiries weekly from those affected by cancer.
Read at www.amny.com
Unable to calculate read time
Collection
[
|
...
]